Glucación no enzimática de proteínas en la diabetes mellitus

Medicina Clinica

Volumn 108, Issue 1, 1997, Pages 23-33

  Iglesias, Pedro ^a,b   Díez, Juan J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; DIABETES MELLITUS; GLYCOSYLATION; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DIABETES MELLITUS; GLYCOSYLATION; HUMANS;

EID: 0041609941     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (176)

1. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Krantz S, Lober M, Henschel L. The nonenzymatic glycation of proteins and nucleic acids, their importance for the development of diabetic complications, possible molecular basis of aging and autoimmunological processes. Exp Clin Endocrinol 1986; 88: 257-269.
3. Trivelli LA, Ranney HN, Lai HT. Hemoglobin components in patients with diabetes mellitus. N Engl J Med 1971; 284: 353-357.
4. Koening RJ, Cerami A. Synthesis of hemoglobin A1c in normal and diabetic mice: potential model of basement membrane thickening. Proc Natl Acad Sci USA 1975; 72: 3.687-3.691.
5. Higgins PJ, Garlick RL, Bunn HF. Glycosylated hemoglobin in human animal red cells: role of glucose permeability. Diabetes 1982; 31: 743-748.
6. Smith RJ, Koenig RJ, Binnerts A, Soeldner JS, Aoki TT. Regulation of hemoglobin A1c formation in human erythrocytes in vitro. Effects of physiologic factors other than glucose. J Clin Invest 1982; 69: 1.164-1168.
7. Bunn HF. Non-enzymatic glycosylation of protein: a form of molecular aging. Schweiz Med Wochenschr 1981; 111: 1.503-1.507.
8. Baynes JW, Bunn HF, Goldstein DE. National Diabetes Data Group: Report of the Expert Committee on glycosylated haemoglobin. Diabetes Care 1984; 7: 602-606.
9. Ashby JP, Deacon AC, Frier BM. Glycosylated haemoglobin measurement and clinical interpretation. Diabet Med 1985; 2: 83-87.
10. Goldstein DE, Little RR, Wiedemeyer HM, England JD, McKenzie EM. Glycated haemoglobins: methodologies and clinical applications. Clin Chem 1986; 32: B64-B70.
11. John WG, Bullock DG, McKenzie F. Methods for the analysis of glycated haemoglobins: what is being measured. Diabet Med 1992; 9: 15-19.
12. Standing SJ, Taylor RP. Glycated haemoglobin: an assessment of high capacity liquid Chromatographic and immunoassay methods. Ann Clin Biochem 1992; 29: 494-505.
13. Buño Soto A, Gómez Rioja R, Jariego Fente C, Grande Aragón C. Determinación de glucohemoglobina en el analizador IMx. Quim Clin 1994; 13: 254-256.
14. Weykamp CW, Penders TJ, Miedema K, Muskiet FAJ, Van der Slik W. Standardization of glycohemoglobin results and reference values in whole blood studied in 103 laboratories using 20 methods. Clin Chem 1995; 41: 82-86.
15. John WG. Glycated haemoglobin analysis assessment of within and between laboratory performance in large UK region Ann Clin Biochem 1987; 24: 453-460.
16. Pickup JC, Crook MA, Tuft P. Blood glucose and glycated haemoglobin measurement in hospital: which method? Diabet Med 1993; 10: 402-411.
17. Ney KA, Colley KJ, Pizzo SV. The standardization of the thiobarbituric acid assay for nonenzymatic glucosylation of human serum albumin. Ann Biochem 1981; 118: 294-300.
18. Day JF, Thorpe SR, Baynes JW. Nonenzymatically glucosylated albumin. J Biol Chem 1979; 254: 595-597.
19. Rendell M, Kao G, Mecherikunnel P, Petersen B, Duhaney R, Nieremberg J et al. Use of aminophenylboronic acid affinity chromatography to measure glycosylated albumin levels. J Lab Clin Med 1985; 105: 63-69.
20. Willey DG, Rosenthal MA, Caldwell S. Glycosylated haemoglobin and plasma glycoprotein assays by affinity chromatography. Diabetologia 1984; 27: 56-58.
21. Hayashi Y, Makino M. Fluorometric measurement of glycosylated albumin in human serum. Clin Chim Acta 1985; 149: 13-19.
22. Fluckiger R, Woodtli T, Berger W. Evaluation of the fructosamine test for the measurement of plasma protein glycation. Diabetologia 1987; 30: 648-652.
23. Fisken RA, Chan AW, Hanlon A, MacFarlane IA. Longitudinal changes in serum fructosamine do not parallel those in glycated haemoglobin in young adults with insulin-dependent diabetes. Clin Chim Acta 1990; 191: 79-86.
24. Baker JR, Metcalf PA, Johnson RN, Newman D, Rietz P. Use of protein-based standards in automated colorimetric determinations of fructosamine in serum. Clin Chem 1985; 31: 1.550-1.554.
25. Baker JR, Johnson RN, Scott DJ. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management. Br Med J 1984; 288: 1.484-1.486.
26. Gillery P, Delattre J, Plaquet R, Stahl A. Standardisation du dosage des fructosamines. Diabet Metab 1993; 19: 321-324.
27. Santiago JV, Davis JE, Fisher F. Hemoglobin A1c levels in a diabetes detection program. J Clin Endocrinol Metab 1978; 47: 578-580.
28. Dods RF, Bolmey C. Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus. Clin Chem 1979; 25: 764-768.
29. Diabetes Mellitus. Report of a WHO Study Group. Technical Report Series 727. Ginebra: OMS, 1985.
30. Lev-Ran A. Glycohemoglobin: its use in the follow-up of diabetes and diagnosis of glucose intolerance. Arch Intern Med 1981; 141: 747-749.
31. Lev-Ran A, Vanderlaan WP. Glycohemoglobins and glucose intolerance. JAMA 1979; 241: 912-914.
32. Boucher BJ, Welch SG, Beer MS. Glycosylated haemoglobins in the diagnosis of diabetes mellitus and for the assessment of chronic hyperglycemia. Diabetologia 1981; 21: 34-36.
33. Bolli G, Compagnucci P, Cartechini MG, Santeujanio F, Cirotto C, Scionti L et al. HbA1 in subjects with abnormal glucose tolerance but normal fasting plasma glucose. Diabetes 1980; 29: 272-277.
34. Cederholm J, Ronquist G, Wibell L. Comparison of glycosylated hemoglobin with oral glucose tolerance test. Diabet Metab 1984; 10: 224-229.
35. Cefalu WT, Ettinger WH, Bell-Farrow AD, Rushing JT. Serum fructosamine as a screening test for diabetes in the elderly: a pilot study. J Am Geriatr Soc 1993; 41: 1.090-1.094.
36. Goldstein DE, Walker B, Rawlings SS, Hess RL, England JD, Peth SB et al. Hemoglobin A1c levels in children and adolescents with diabetes mellitus. Diabet Care 1980; 3: 503-507.
37. Agardh CD, Tallroth G. Lack of correlation between glycosylated haemoglobin concentrations and number of daily insulin injections: cross sectional study in care of ambulatory diabetes. Br Med J 1985; 291: 622.
38. Mecklenburg RS, Benson EA, Benson JW Jr, Blumenstein BA, Fredlund PN, Guinn TS et al. Long-term metabolic control with insulin pump therapy. Report of experience with 127 patients. N Engl J Med 1985; 313: 465-468.
39. Wywial M, Silanczyk A, Wywial R, Jakubowska D, Zmudzinski W, Kokot S. Oznaczanie hemoglobiny glikozylowanej przydatna metoda kontroli przebiegu cukrzyci typu II u chorych podejrzanych o niepelne wyrownanie. Pol Arch Med Wewn 1993; 90: 35-41.
40. Blanc MH, Barnett DM, Gleason RE, Dunn PJ, Soeldner JS. Hemoglobin Ale compared with three conventional measures of diabetes control. Diabet Care 1981; 4: 349-353.
41. Graf RJ, Halter JB, Porte D. Glycosylated hemoglobin in normal subjects and subjects with maturity onset diabetes. Diabetes 1978; 27: 834-839.
42. Dolhofer R, Wieland OH. Glycosylation of serum albumin: elevated glucosyl albumin in diabetic patients. FEBS Lett 1979; 103: 282-286.
43. Dolhofer R, Wieland OH. Increased glycosylation of serum albumin in diabetes mellitus. Diabetes 1980; 29: 417-422.
44. Dolhofer R, Renner R, Wieland OH. Different behavior of haemoglobin A1a-c and glucosyl-albumin levels during recovery from diabetic ketoacidosis and non-acidotic coma. Diabetologia 1981; 21: 211-215.
45. Kempf SF, Creech RH, Horn TR. Glycosylated albumin and transferrin: short term markers of blood glucose control. J Pediatr 1984; 105: 394-398.
46. McFarland KF, Catalano EW, Day JF, Thorpe SR, Baynes JW. Nonenzymatic glucosylation of serum proteins In diabetes mellitus. Diabetes 1979; 28: 1.011-1.014.
47. Yue DK, Morris K, McLennan S, Turtle JR. Glycosylation of plasma protein and its relation to glycosylated hemoglobin in diabetes. Diabetes 1980; 29: 296-300.
48. Grande C, Díez JJ, De la Morena ML, Ezquieta B, Luna R, Pallardo LF. Evolución de parámetros de glucación proteica a lo largo de la gestación en pacientes diabéticas. Endocrinología 1989; 36: 322-326.
49. Miller E, Hare JW, Cloherty JP, Dunn PJ, Gleason RE, Soeldner S et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304: 1.331-1.334.
50. Ylinen K, Aula P, Stenman UH, Kesäniemi-Kuokkanen T, Teramo K. Risk of minor and major fetal malformations in diabetics with high haemoglobin A1c values in early pregnancy. Br Med J 1984; 289: 345-346.
51. Díez JJ, Pallardo LF, Grande C. Hemoglobina glucosilada y fructosamina sanguíneas y péptido C en el líquido amniótico de gestantes diabéticas: relación con el peso fetal. Med Clin (Barc) 1988; 90: 484-489.
52. Dunn PJ, Cole RA, Soeldner JS, Gleason RE. Stability of hemoglobin A1c levels on repetitive determination in diabetic outpatients. J Clin Endocrinol Metab 1981; 52: 1.019-1.022.
53. Watala C, Gwozdzinski K, Malek M. Direct evidence for the alterations in protein structure and conformation upon in vitro nonenzymatic glycosylation. Int J Biochem 1992; 24: 1.295-1.302.
54. Cerami A, Vlassara H, Brownlee M. Glucose and aging. Sci Am 1987; 5: 90-96.
55. Nakayama H, Taneda S, Kuwajima S, Aoki S, Kuroda Y, Misawa K et al. Production and caracterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 1989; 162: 740-745.
56. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and phatogenesis of diabetic complications. Ann Intern Med 1984; 101: 527-537.
57. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation and products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1.315-1.321.
58. Monnier VM, Sell DR, Abdul-Karim FW, Emancipator SN. Collagen browning and cross-linking are increased in chronic experimental hyperglycemia. Diabet 1988; 37: 867-872.
59. Sensi M, Pricci F, Andreani D, Di Mario U. Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res 1991; 16: 1-9.
60. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabet Care 1992; 15: 1.835-1.843.
61. Monnier V. Glycosylation non-enzymatique des proteines. Complications du diabete, du vieillissement et de l'insuffisance renale. Presse Med 1993; 22: 1.413-1.418.
62. Wu JT. Review of diabetes: identification of markers for early detection, glycemic control, and monitoring clinical complications. J Clin Lab Anal 1993; 7: 293-300.
63. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
64. Sell DR, Nagaraj RH, Grandhee SK, Odetti P, Lapolla A, Fogarty J et al. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabet Metab Rev 1991; 7: 239-251.
65. Niwa T, Takeda N, Yoshizumi H, Tatematsu A, Ohara M, Tomiyama S et al. Presence of 3-deoxyglucosone, a potent crosslinking intermediated of Maillard reaction, in diabetic serum. Biochem Biophys Res Comm 1993; 196: 837-843.
66. Vlassara H, Brownlee M, Manogue K, Dinarello CA, Pasagian A, Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240: 1.546-1.548.
67. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 1993; 91: 2.155-2.168.
68. Vlassara H, Brownlee M, Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82: 5.588-5.592.
69. Vlassara H, Moldawer L, Chan B. Macrophage/monocyte receptor for non-enzymatically glycosylated proteins is upregulated by cachectin/tumor necrosis factor. J Clin Invest 1989; 84: 1.813-1.820.
70. Radoff S, Cerami A, Vlassara H. Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line RAW 264.7. Diabetes 1990; 39: 1.510-1.518.
71. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993; 178: 2.165-2.172.
72. Brett J, Schmitdt AM, Yan SD, Zou YS, Weidman E, Pinsky D et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1.699-1.712.
73. Wu VY, Cohen MP. Identification of aortic endothelial cell binding proteins for Amadori adducts in glycated albumin. Biochem Biophys Res Comm 1993; 30: 1.131-1.136.
74. Kelly SB, Olerud JE, Witztum JL, Curtiss LK, Gown AM, Odland GF. A method for localizing the early products of nonenzymatic glycosylation in fixed tissue. J Invest Derm 1989; 93: 327-331.
75. Bucala R, Model P, Cerami A. Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expresion. Proc Natl Acad Sci USA 1984; 81: 105-109.
76. De Bellis D, Horowitz Ml. In vitro studies of histone glycation. Biochem Biophys Acta 1987; 926: 365-368.
77. Liebich HM, Gesele E, Wirth C, Woll J, Jobst K, Lakatos A. Non-enzymatic glycation of histones. Biol Mass Spectrom 1993; 22: 121-123.
78. Lorenzi M, Montisano DF, Toledo S, Barrieux A. High glucose and DNA damage in endothelial cells. J Clin Invest 1986; 77: 322-325.
79. Penn A, Garte SJ, Warren L, Nesta D, Mindich B. Transformin gene in human atherosclerotic plaque DNA. Proc Natl Acad Sci USA 1986; 83: 7.951-7.955.
80. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2.463-2.469.
81. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41: 1.286-1.292.
82. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91: 2.470-2.478.
83. Aoki Y, Yazaki K, Shirotori K, Yanagisawa Y, Oguchi H, Kiyosawa K et al. Stiffening of connective tissue in elderly diabetic patients: relevance to diabetic nephropathy and oxidative stress. Diabetologia 1993; 36: 79-83.
84. Tsilbary EC, Charonis AS, Reger LA, Wonlhueter RM, Furcht LT. The effect of nonenzymatic glycosilation on the binding of the main noncollagenous NC1 domain at to type IV collagen. J Biol Chem 1988; 263: 4.302-4.308.
85. Charonis AS, Tsilibary EC. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation. Diabetes 1992; 41 (Supl 2): 49-51.
86. Lyons TJ, Patrick JS, Baines JW, Colwell JA, Lopes-Virella MF. Glycosylation of low density lipoprotein in patients with type 1 diabetes: correlations with other parameters of glycaemic control. Diabetologia 1986; 29: 685-689.
87. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosilation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6.434-6.438.
88. Lyons TJ. Lipoprotein glycation and its metabolic consequences. Diabetes 1992; 41 (Supl 2): 67-73.
89. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993; 71: 26B-31B.
90. Cohen MP, Lautenslager G, Shea E. Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Biochem 1993; 31: 707-713.
91. Lopes-Virella MF, Sherer GK, Lees AM, Wohlthann H, Mayfield R, Sagel J et al. Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia 1982; 22: 430-436.
92. Ponsin G, Calvo C, Berthezene F. Metabolic consequences of the nonenzymatic glucosilation of apolipoproteins. Diabet Metab 1991; 17: 497-502.
93. Sobenin IA, Tertov W, Koschinsky T, Bunting CE, Slavina ES, Dedov II et al. Modified low density lipoproteins from diabetic patients causes cholesterol accumulation in human intimai aortic cells. Atherosclerosis 1993; 100: 41-54.
94. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Comm 1990; 173: 932-939.
95. Lyons TJ. Oxidized low density lipoproteins- a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med 1991; 8: 411-419.
96. Morel DW, Hessler JR, Chisol GM. Low density lipoprotein cytotoxity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1.070-1.076.
97. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993; 102: 63-67.
98. Lopes-Virella MF, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 1992; 41 (Supl 2): 86-91.
99. Gisinger CH, Lopes-Virella MF. Lipoprotein-immune complexes and diabetic vascular complications. Diabetes 1992; 41 (Supl 2): 92-96.
100. Curtiss LK, Witztum JL. Plasma apo-lipoproteins A-I, A-II, B, C-I, and E are glycosylated in hyperglycemic diabetic subjects. Diabetes 1985; 34: 452-461.
101. Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes 1990; 39: 1.257-1.263.
102. Duell PB, Oram JF, Bierman EL. Noenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991; 40: 377-384.
103. Calvo C, Verdugo C. Association in vivo of glycated apolipoprotein A-I with high density lipoproteins. Eur J Clin Chem Clin Biochem 1992; 30: 3-5.
104. Calvo C, Ulloa N, Del Pozo R, Verdugo C. Decreased activation of lecitin. cholesterol acyltransferase by glycated apolipoprotein A-I. Eur J Clin Chem Clin Biochem 1993; 31: 217-220.
105. Witztum JL, Fisher M, Pietro T, Steinbrecher UP, Elam RL. Nonenzymatic glucosilation of high-density lipoprotein accelerates its catabolism in guinea pigs. Diabetes 1982; 31: 1.029-1.032.
106. Mamo JC, Szeto L, Steiner G. Glycation of very low density lipoprotein form rat plasma impairs its catabolism. Diabetologia 1990; 33: 339-345.
107. Brownlee M, Pongor S, Cerami A. Covalent attachement of soluble proteins by nonenzymatically glycosylated collagen. role in the situ formation of immune complex. J Exp Med 1983; 158: 1.739-1.744.
108. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34: 938-941.
109. Pamplona R, Bellmunt MJ, Portera M, Prat J. Mechanisms of glycation in atherogenesis. Med Hypothesies 1993; 40: 174-181.
110. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1.110-1.115.
111. Airaksinen KE, Salmela PI, Linnaluoto MK, Ikaheimo MJ, Ahola K, Ryhanen LJ. Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Crdiovasc Res 1993; 27: 942-945.
112. Huijberts MS, Wolffenbuttel BH, Boudier HA, Crijns FR, Kruseman AC, Poitevin P et al. Aminoguanidine treatment increases elasticity and decreasaes fluid filtration of large arteries from diabetics rats. J Clin Invest 1993; 92: 1.407-1.411.
113. Tomizawa H, Yamazaki M, Kunika K, Itakura M, Yamashita K. Association of elastin glycation and calcium deposit in diabetic rat aorta. Diabet Res Clin Pract 1993; 19: 1-8.
114. Nakamura Y, Horii Y, Nishino T, Sakaguchi Y, Kagoshima T, Dohi K et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1.649-1.656.
115. Morel DW, DiCorleto PE, Chilsom G. Endothelial and smooth muscle cells alters LDL in vitro by free radical oxidation. Arteriosclerosis 1984; 4: 357-364.
116. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1.119-1.125.
117. Cohen I, Burk D, Fullerton RJ, Veis A, Green D. Nonenzymatic glycation of human blood platelet proteins. Thromb Res 1989; 55: 341-349.
118. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1.387-1-407.
119. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci 1986; 83: 4.533-4.537.
120. Brownlee M, Vlassara H, Cerami A. Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation: possible role in fibrin deposition in diabetes. Diabetes 1984; 33: 532-535.
121. Jones RL, Peterson CM. Hematologic alterations in diabetes mellitus. Am J Med 1981; 70: 339-352.
122. Watala C. Hyperglycaemia alters the physico-chemical properties of proteins in erythrocyte membranes of diabetic patients. Int J Biochem 1992; 24: 1.755-1.761.
123. Watala C, Witas H, Olszowska L, Piasecki W. The association between erythrocyte internal viscosity, protein non-enzymatic glycosylation and erithrocyte membrane dynamic properties in juvenile diabetes mellitus. Int J Exp Pathol 1992; 73: 655-663.
124. Watala C. Role of nonenzymatic glycosilation of proteins in disorders of erythrocytes and blood platelets in diabetes mellitus. Acta Haematol Pol 1993; 24: 95-101.
125. Peterson CHM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML. Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med 1977; 86: 425-429.
126. McMillan DE, Utterback NG, LaPuma J. Reduced erythrocyte deforambility in diabetes. Diabetes 1978; 27: 895-901.
127. Kuwajima S. Immunochemical determination of advanced glycation end products in erythrocyte peripheral-membrane proteins from diabetic patients. Hokkaido Igaku Zasshi 1993; 68: 695-704.
128. Bilan PJ, Klip A. Glycation of the human erythrocyte glucose transporte in vitro and its functional consequences. Biochem J 1990; 268: 661-667.
129. González Flecha FL, Castello PR, Caride AJ, Gagliardino JJ, Rossi JP. The erythrocyte calcium pump is inhibited by non-enzymatic glycation: studies in situ and with the purified enzyme. Biochem J 1993; 293: 369-375.
130. Kawamura N, Ookawara T, Suzuki K, Konishi K, Mino M, Taniguchi N. Increased glycated Cu,Zn-superoxide dismutase levels in erythrocytes of patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992; 74: 1.352-1.354.
131. Dolhofer Bliesener R, Gerbitz KD. Impairment by glycation of immunoglobulin G Fc fragment function. Scand J Clin Lab Invest 1990; 50: 739-746.
132. Dohofer Bliesener R, Gerbitz KD. Effect of nonenzymatic glycation on the structure of immunoglobulin G, Biol Chem Hoppe Seyler 1990; 371: 693-697.
133. Hennessey PJ, Black CT, Andrassy RJ. Nonenzymatic glycosilation of immunoglobulin G impairs complement fixation. JPEN J Parent Enterai Nutr 1991; 15: 60-64.
134. Kennedy DM, Skillen AW, Self CH. Glycation increases the vascular clearance rate of IgG in mice. Clin Exp Immunol 1993; 94: 447-451.
135. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-408.
136. Barnett AH. Pathogenesis of diabetic microangiopathy: an overview. Am J Med 1991; 90 (Supl 6A): 67-73.
137. Brouhard BH. Advanced glycosylation end products (AGE) and diabetic nephropathy. Diabet Care 1992; 15: 302-303.
138. Narins RG. Diabetic Nephropathy: can the natural history be modified? Am J Med 1991; 21 (Supl 2A): 70-75.
139. Beisswenger PJ, Moore LL, Brinck Johnsen T, Curphey TJ. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 1993; 92: 212-217.
140. Skolnick EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991; 174: 931-939.
141. Crowley ST, Brownlee M, Edelstein D, Satriano JA, Morit T, Singhal PC et al. Effects of nonenzymatic glycosylation of mesangial matrix on proliferation of mesangial cells. Diabetes 1991; 40: 540-547.
142. Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis 1993; 22: 72-82.
143. Ziyadeh EN, Cohen MP. Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol Cell Biochem 1993; 125: 19-25.
144. Ziyadeh FN. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int 1993; 43: 114-120.
145. Cohen MP, Ziyadeh FN. Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int 1994; 45: 475-487.
146. Liang JN. Nonenzymatic advanced glycation in the lens membranes. Exp Eye Res 1993; 57: 45-49.
147. Swamy MS, Abraham A, Abraham EC. Glycation of human lens proteins: preferential glycation of alpha A subunits. Exp Eye Res 1992; 54: 337-345.
148. Kamei A. Glycation and insolubility of human lens protein. Chem Pharm Bull Tokyo 1992; 40: 2.787-2.791.
149. Van Boekel MA, Hoenders HJ. Glycation of cristallins in lenses from aging and diabetic individuals. FEBS Lett 1992; 314: 1-4.
150. Swamy MS, Abraham EC. Glycation of lens membrane intrinsic proteins. Curr Eye Res 1992; 11: 833-842.
151. Abraham EC, Swamy MS, Perry RE: Nonenzymatic glycosilation (glycation) of lens crystallins in diabetes and aging. Prog Clin Biol Res 1989; 304: 123-139.
152. Swamy MS, Tsai C, Abraham A, Abraham EC. Glycation mediated lens cyrstallin aggregation and cross-linking by various sugars and sugar phosphates in vitro. Exp Eye Res 1993; 56: 177-185.
153. Jones RH, Hothersall JS. The effect of diabetes and dietary ascorbate supplementation on the oxidative modification of rat lens beta L crystallin. Biochem Med Metab Biol 1993; 50: 197-209.
154. Blakytny R, Harding JJ. Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 1992; 54: 509-518.
155. Sell DR, Monnier VM. End-stage renal disease and diabetes catalyze the formation of a pentose-derived cross-link from aging human collagen. J Clin Invest 1990; 85: 380-384.
156. Sell DR, Carlson EC, Monnier VM. Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia 1993; 36: 936-941.
157. Huntley AC. Cutaneous manifestations of diabetes mellitus. Dermatol Clin 1989; 7: 531-546.
158. Sueki H, Nozaki S, Numuzawa S, Aoki K, Kiroiwa Y, Fujisawa R. Effect of non-enzymatic glycosylation and heating on browning of human stratum corneun and nail. Dermatologica 1991; 183: 197-202.
159. Michailova M, Keita Y, Caspary S, Solem E, Kratzer W, Worner G et al. Inhibitory effect of vitamin B6 on nonenzymatic glycation of albumin and hemoglobin. Int J Clin Pharmacol Ther Toxicol 1992; 30: 547-548.
160. Hayakawa M, Shibata M. The in vivo and in vitro inhibition of protein glycosylation and diabetic vascular basement membrane thickening by pyridoxal-5′-phosphate. J Nutr Sci Vitaminol Tokyo 1991; 37: 149-159.
161. Keita Y, Michailova M, Kratzer W, Worner G, Worner W, Rietbrock N. Influence de la penicillamine on the formation of early-non-enzymatic glycation products of human serum proteins. Int J Clin Pharmacol Ther Toxicol 1992; 30: 441-442.
162. Suzuki YJ, Tsuchiya M, Packer L. Lipoate prevents glucose-induced protein modifications. Free Radic Res Commun 1992; 17: 211-217.
163. Le Guen CA, Bain S, Barnett AH, Lunec J. Captopril inhibits the fluorescence development associated with glycation of proteins. Agents Actions 1992; 36: 264-270.
164. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabet Care 1991; 14: 68-72.
165. Ceriello A, Quatraro A, Giugliano D. New insights on non-enzymatic glycosylation may lead to therapeutic approches for the prevention of diabetic complications. Diabet Med 1992; 9: 297-299.
166. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycoslation of proteins. Diabetes 1992; 41: 167-173.
167. Sensi M, Bruno MR, Pozzilli P. In vitro inhibition of nonenzymic glycosylation induced by aspirin. Med Sci Res 1987; 15: 99-100.
168. Cohen MP, Klepser H, Wu VY. Effect of alpha-glucosidase inhibition on the nonenzymatic glycation of glomerular basement membrane. Gen Pharmacol 1991; 22: 515-519.
169. Sensi M, De Rossi MG, Celi FS, Cristina A, Rosati C, Perrett D et al. Dlysine reduces the non-enzymatic glycation of proteins in experimental diabetes mellitus in rats. Diabetologia 1993; 36: 797-801.
170. Edelstein D, Brownlee M. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992; 41: 26-29.
171. Shoff SM, Mares-Perlman JA, Cruickshanks KJ, Klein R, Klein BE, Ritter LL. Glycosylated hemoglobin concentrations and vitamin E, vitamin C, and beta-carotene intake in diabetic and nondiabetic older adults. Am J Clin Nutr 1993; 58: 412-416.
172. Hammes HP, Martin S, Federlin K, Gersen K, Brownlee M. Aminoguanidine treatment inhibits the development of accelerated diabetic retinopathy. Proc Natl Acad Sci 1991; 88: 11.555-11.558.
173. Hammes HP, Brownle M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-35.
174. Vagishashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
175. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotoin-diabetic rats. Diabetologia 1992; 35: 946-950.
176. Cameron NE, Cotter MA. Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence form experimental studies. Diabet Med 1993; 10: 593-605.